

# CITATION REPORT

List of articles citing

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

DOI: 10.1126/scitranslmed.3001708

Science Translational Medicine, 2011, 3, 64ra1.

**Source:** <https://exaly.com/paper-pdf/50395932/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
306	Chimpanzees: a model "model system" for social responsiveness. <b>2011</b> , 50, 438-40		
305	Fragile X syndrome: an update on developing treatment modalities. <b>2011</b> , 2, 402-10		16
304	Allosteric modulation of metabotropic glutamate receptors. <b>2011</b> , 62, 37-77		42
303	Fragile X syndrome: the GABAergic system and circuit dysfunction. <b>2011</b> , 33, 349-64		119
302	Genetic influence on the working memory circuitry: behavior, structure, function and extensions to illness. <b>2011</b> , 225, 610-22		33
301	Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability. <b>2011</b> , 24, 387-97		24
300	Fragile x syndrome. <b>2011</b> , 12, 216-24		109
299	Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation. <b>2011</b> , 79, 508-10		1
298	CGG repeat in the FMR1 gene: size matters. <b>2011</b> , 80, 214-25		115
297	Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency. <b>2011</b> , 19,		10
296	Promoter predicts drug results. <b>2011</b> , 469, 269-269		
295	The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. <b>2011</b> , 81, 1078-86		21
294	Targeted treatments for fragile X syndrome. <b>2011</b> , 3, 193-210		76
293	FMR1 premutation and full mutation molecular mechanisms related to autism. <b>2011</b> , 3, 211-24		64
292	Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis. <b>2011</b> , 2, 7		102
291	The FRAXopathies: definition, overview, and update. <b>2011</b> , 155A, 1803-16		33
290	A majority of parents accept newborn screening for fragile X. <b>2011</b> , 155A, viii-ix		1

289	Advances in understanding fragile X syndrome and related disorders. <b>2011</b> , 23, 601-6		18
288	Translating glutamate: from pathophysiology to treatment. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 102m725		127
287	Autism: a "critical period" disorder?. <b>2011</b> , 2011, 921680		182
286	On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. <b>2011</b> , 33, 414-27		26
285	Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. <b>2011</b> , 18, 774-8		35
284	Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. <b>2012</b> , 37, 178-95		81
283	Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. <b>2012</b> , 2012, 843016		27
282	Next-generation treatments for mental disorders. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 155ps19	17.5	111
281	Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 152ra128	17.5	184
280	Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome. <b>2012</b> , 25, 112-24		22
279	Trialing targeted therapies for autism. <b>2012</b> , 18, 1746-7		
278	Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. <b>2012</b> , 4,		488
277	Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. <b>2012</b> , 2012, 280813		32
276	Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders. <b>2012</b> , 2012, 486402		32
275	Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 131ra51	17.5	180
274	Caregiver opinions about fragile X population screening. <b>2012</b> , 14, 115-21		20
273	Health and economic consequences of fragile X syndrome for caregivers. <b>2012</b> , 33, 705-12		53
272	Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. <b>2012</b> , 33, 62-9		45

271	Treatment of neurodevelopmental disorders in adulthood. <b>2012</b> , 32, 14074-9	48
270	Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 152ra127	17.5 232
269	Treatments: In the waiting room. <b>2012</b> , 491, S14-6	1
268	De novo gene disruptions in children on the autistic spectrum. <b>2012</b> , 74, 285-99	1052
267	Sensitive time-windows for susceptibility in neurodevelopmental disorders. <b>2012</b> , 35, 335-44	69
266	Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. <b>2012</b> , 338, 128-32	210
265	New models for considering the role of medication in the treatment and elucidation of the etiology of autism. <b>2012</b> , 14, 726-31	5
264	TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME. <b>2012</b> , 6, 1311-1320	35
263	Fragile X syndrome: a pilot proton magnetic resonance spectroscopy study in premutation carriers. <b>2012</b> , 4, 23	3
262	mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders. <b>2012</b> , 71-88	3
261	CHAPTER 15:Emerging Research towards the Understanding and Treatment of Autism. <b>2012</b> , 384-415	
260	Mining and modeling human genetics for autism therapeutics. <b>2012</b> , 22, 902-10	8
259	mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders. <b>2012</b> , 21, 1819-25	33
258	Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. <b>2012</b> , 15, 431-40, S1	188
257	Epigenomics Impact for Drug Safety Sciences. <b>2012</b> , 365-385	3
256	Pathways to drug development for autism spectrum disorders. <b>2012</b> , 91, 189-200	39
255	Tweaking the social network. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 131fs9	17.5
254	FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. <b>2012</b> , 4, 100	198

253	Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110 $\beta$ selective inhibitor. <b>2012</b> , 18, 336-45	54
252	Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. <b>2012</b> , 122, 4314-22	203
251	Genetic testing of adults with intellectual disability. <b>2012</b> , 36, 409-413	4
250	Emerging Role of Epigenetics in Human Neurodevelopmental Disorders. <b>2012</b> , 153-173	0
249	Fragile X syndrome and targeted treatment trials. <b>2012</b> , 54, 297-335	77
248	Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments. <b>2012</b> , 37, 196-212	91
247	Molecular mechanisms of fragile X syndrome: a twenty-year perspective. <b>2012</b> , 7, 219-45	374
246	Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment. <b>2012</b> , 42, 1377-92	113
245	G protein-coupled receptor signalling in astrocytes in health and disease: a focus on metabotropic glutamate receptors. <b>2012</b> , 84, 249-59	39
244	Self-injurious behaviour in intellectual disability syndromes: evidence for aberrant pain signalling as a contributing factor. <b>2012</b> , 56, 441-52	33
243	A Learning platform Approach to outcome measurement in fragile X syndrome: a preliminary psychometric study. <b>2012</b> , 56, 947-60	9
242	The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. <b>2012</b> , 13, 13	13
241	Fragile X-associated disorders: a clinical overview. <b>2012</b> , 259, 401-13	75
240	Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. <b>2013</b> , 4, 15	37
239	Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. <b>2013</b> , 228, 75-84	74
238	Fresh from the designation pipeline: orphan drugs recently designated in the European Union. <b>2013</b> , 1, 249-253	1
237	Fragile X syndrome: clinical, cytogenetic and molecular screening among autism spectrum disorder children in Indonesia. <b>2013</b> , 84, 577-80	6
236	Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. <b>2013</b> , 43, 739-46	34

235	The genetic landscapes of autism spectrum disorders. <b>2013</b> , 14, 191-213	274
234	Fragile X syndrome: an aging perspective. <b>2013</b> , 18, 68-74	10
233	Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. <b>2013</b> , 73, 303-14	58
232	Drugmakers plow more resources into autism. <b>2013</b> , 31, 367-9	
231	mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. <b>2013</b> , 66, 40-52	94
230	Fragile X Syndrome and X-linked Intellectual Disability. <b>2013</b> , 1-27	
229	Hydrocarbons (jet fuel JP-8) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. <b>2013</b> , 36, 104-16	175
228	A quantitative homogeneous assay for fragile X mental retardation 1 protein. <b>2013</b> , 5, 8	16
227	Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. <b>2013</b> , 23, 5779-85	29
226	Drug discovery for autism spectrum disorder: challenges and opportunities. <b>2013</b> , 12, 777-90	72
225	Dendritic protein synthesis in the normal and diseased brain. <b>2013</b> , 232, 106-27	33
224	Fragile X Syndrome and Autism Spectrum Disorders. <b>2013</b> , 409-419	3
223	An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. <b>2013</b> , 68, 2-82	159
222	Fragile X syndrome: From protein function to therapy. <b>2013</b> , 161A, 2809-21	72
221	Epigenetics, fragile X syndrome and transcriptional therapy. <b>2013</b> , 161A, 2797-808	27
220	Electrocortical changes associated with minocycline treatment in fragile X syndrome. <b>2013</b> , 27, 956-63	78
219	Newborn screening and cascade testing for FMR1 mutations. <b>2013</b> , 161A, 59-69	19
218	Maternal attitudes to newborn screening for fragile X syndrome. <b>2013</b> , 161A, 301-11	19

217	Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators. <b>2013</b> , 23, 1398-406	9
216	Drosophila strategies to study psychiatric disorders. <b>2013</b> , 92, 1-11	53
215	Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism. <b>2013</b> , 68, 210-22	26
214	Using as a tool to identify Pharmacological Therapies for Fragile X Syndrome. <b>2012</b> , 10, e129-e136	11
213	Epilepsy drives autism in neurodevelopmental disorders. <b>2013</b> , 55, 101-2	10
212	Translational Neuroimaging for Drug Discovery and Development in Autism Spectrum Disorders: Guidance from Clinical Imaging and Preclinical Research. <b>2013</b> , 245-280	
211	The unstable repeats--three evolving faces of neurological disease. <b>2013</b> , 77, 825-43	151
210	Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma. <b>2013</b> , 405, 215-23	3
209	mGlu5 negative allosteric modulators: a patent review (2010-2012). <b>2013</b> , 23, 393-408	56
208	Fragile X syndrome: from targets to treatments. <b>2013</b> , 68, 83-96	35
207	Prospects for improving brain function in individuals with Down syndrome. <b>2013</b> , 27, 679-702	52
206	Progress toward treatments for synaptic defects in autism. <b>2013</b> , 19, 685-94	141
205	Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. <b>2013</b> , 239, 72-9	73
204	Phase II and III drugs for the treatment of fragile X syndrome. <b>2013</b> , 1, 47-65	1
203	Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. <b>2013</b> , 3, e003660	15
202	Fragile X-related element 2 methylation analysis may provide a suitable option for inclusion of fragile X syndrome and/or sex chromosome aneuploidy into newborn screening: a technical validation study. <b>2013</b> , 15, 290-8	18
201	Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013). <b>2013</b> , 2, 767-802	13
200	A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. <b>2013</b> , 34, 147-55	183

199	Development of an expressive language sampling procedure in fragile X syndrome: a pilot study. <b>2013</b> , 34, 245-51	38
198	Outcome measures for clinical trials in fragile X syndrome. <b>2013</b> , 34, 508-22	100
197	Power of rare diseases: found in translation. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 201ps11	17.5 22
196	Fragile X Clinical Features and Neurobiology. <b>2013</b> , 631-650	
195	Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice. <b>2013</b> , 22, 1180-92	41
194	Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. <b>2013</b> , 41, 1626-41	21
193	Genetic defects behind fragile X-related disorders more common: researchers find the incidence of one type of FMR1 allele double its previous estimate in males. <b>2013</b> , 161A, x-xi	
192	FRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIES. <b>2013</b> , 9, 53-58	15
191	Progress toward therapeutic potential for AFQ056 in Fragile X syndrome. <b>2013</b> , 5, 45-54	4
190	mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotion. <b>2013</b> , 8, e70415	26
189	The Drosophila DmGluRA is required for social interaction and memory. <b>2013</b> , 4, 64	9
188	Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. <b>2014</b> , 12, 19-30	11
187	Molecular Mechanisms of Neurological Disease. <b>2014</b> , 639-661	2
186	2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. <b>2014</b> , 8, 70	26
185	Modulation of the GABAergic pathway for the treatment of fragile X syndrome. <b>2014</b> , 10, 1769-79	45
184	Development of mavoglurant and its potential for the treatment of fragile X syndrome. <b>2014</b> , 23, 125-34	21
183	A combination of ascorbic acid and folic acid to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial. <b>2014</b> , 15, 345	8
182	Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders. <b>2014</b> , 5, 239	10



181	Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics. <b>2014</b> , 5, 68	51
180	Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome. <b>2014</b> , 164A, 141-55	35
179	Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. <b>2014</b> , 111, 4596-601	140
178	Parent ratings of ability to consent for clinical trials in fragile X syndrome. <b>2014</b> , 9, 18-28	11
177	Development of allosteric modulators of GPCRs for treatment of CNS disorders. <b>2014</b> , 61, 55-71	164
176	Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. <b>2014</b> , 35, 1072-86	53
175	Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. <b>2014</b> , 50, 297-302	57
174	Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. <b>2014</b> , 231, 1227-35	59
173	Epilepsy associated with autism and attention deficit hyperactivity disorder: is there a genetic link?. <b>2014</b> , 36, 185-93	47
172	Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. <b>2014</b> , 231, 1217-26	66
171	The challenges of clinical trials in fragile X syndrome. <b>2014</b> , 231, 1237-50	76
170	Neurobiology of autism gene products: towards pathogenesis and drug targets. <b>2014</b> , 231, 1037-62	57
169	Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. <b>2014</b> , 14, 23	21
168	The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. <b>2014</b> , 121, 891-905	116
167	A blueprint for research on Shankopathies: a view from research on autism spectrum disorder. <b>2014</b> , 74, 85-112	9
166	Lithium: a promising treatment for fragile X syndrome. <b>2014</b> , 5, 477-83	24
165	Topological methods reveal high and low functioning neuro-phenotypes within fragile X syndrome. <b>2014</b> , 35, 4904-15	27
164	Using genetic findings in autism for the development of new pharmaceutical compounds. <b>2014</b> , 231, 1063-78	15

163	From FMRP function to potential therapies for fragile X syndrome. <b>2014</b> , 39, 1016-31	33
162	Biomarkers in autism spectrum disorder: the old and the new. <b>2014</b> , 231, 1201-16	117
161	Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome. <b>2014</b> , 119, 1-16	10
160	Activity-dependent alterations in the sensitivity to BDNF-TrkB signaling may promote excessive dendritic arborization and spinogenesis in fragile X syndrome in order to compensate for compromised postsynaptic activity. <b>2014</b> , 83, 429-35	8
159	Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. <b>2014</b> , 164A, 2834-42	53
158	Fragile X syndrome due to a missense mutation. <b>2014</b> , 22, 1185-9	60
157	Etiology of autism spectrum disorder: a genomics perspective. <b>2014</b> , 16, 501	11
156	AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. <b>2014</b> , 22, 5790-803	37
155	Fragile X syndrome neurobiology translates into rational therapy. <b>2014</b> , 19, 510-9	28
154	Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. <b>2014</b> , 24, 3307-14	9
153	Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. <b>2014</b> , 75, 198-206	91
152	Translational endpoints in fragile X syndrome. <b>2014</b> , 46 Pt 2, 256-69	12
151	Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. <b>2014</b> , 26, 2284-97	35
150	Drosophila models of early onset cognitive disorders and their clinical applications. <b>2014</b> , 46 Pt 2, 326-42	48
149	A novel methylation PCR that offers standardized determination of FMR1 methylation and CGG repeat length without southern blot analysis. <b>2014</b> , 16, 23-31	27
148	Targeted treatments in fragile X syndrome. <b>2014</b> , 2, 531-543	10
147	Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes. <b>2014</b> , 74, 197-206	8
146	Emerging pharmacologic treatment options for fragile X syndrome. <b>2015</b> , 8, 75-93	20

145	Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. <b>2015</b> , 9, 55	22
144	Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. <b>2015</b> , 10, e0133316	30
143	Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back. <b>2015</b> , 12, 584-608	68
142	Addressing the Genetics of Human Mental Health Disorders in Model Organisms. <b>2015</b> , 16, 173-97	24
141	High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome. <b>2015</b> , 20, 1101-11	67
140	Therapeutic approaches for the future treatment of Fragile X. <b>2015</b> , 4, 6-21	2
139	From de novo mutations to personalized therapeutic interventions in autism. <b>2015</b> , 66, 487-507	32
138	Function and information content of DNA methylation. <b>2015</b> , 517, 321-6	1207
137	Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. <b>2015</b> , 20, 124-34	77
136	Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. <b>2015</b> , 40, 755-65	36
135	Developing a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome. <b>2015</b> , 24, 305-14	16
134	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <b>2015</b> , 25, 1513-31	37
133	Fragile X-Associated Disorders. <b>2015</b> , 183-195	1
132	Fragile X-Associated Disorders. <b>2015</b> , 120-129	
131	Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects. <b>2015</b> , 32, 1764-78	10
130	Relationship among Glutamine, $\gamma$ -Aminobutyric Acid, and Social Cognition in Autism Spectrum Disorders. <b>2015</b> , 25, 314-22	59
129	Autism and Glutamate. <b>2015</b> , 243-256	2
128	Dynamics and modulation of metabotropic glutamate receptors. <b>2015</b> , 20, 95-101	48

127	The quest for targeted therapy in fragile X syndrome. <b>2015</b> , 19, 1277-81	11
126	Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish. <b>2015</b> , 8, 647-56	27
125	ESCI award lecture: regulation, function and biomarker potential of DNA methylation. <b>2015</b> , 45, 288-93	8
124	Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzotrile). <b>2015</b> , 58, 6653-64	126
123	Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2. <b>2015</b> , 35, 11125-32	39
122	Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date. <b>2015</b> , 29, 453-63	18
121	Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome. <b>2015</b> , 44, 250-63	31
120	The Central Role of Etiology in Science and Practice in Intellectual Disability. <b>2016</b> , 50, 33-69	6
119	Fragile X Syndrome. <b>2016</b> , 325-346	2
118	Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms. <b>2016</b> , 2016, 8781725	8
117	Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome. <b>2016</b> , 2016, 9353929	5
116	Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models. <b>2016</b> , 10, 136	23
115	Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome. <b>2016</b> , 7,	17
114	Review of targeted treatments in fragile X syndrome. <b>2016</b> , 5, 158-67	23
113	A Novel Analog Reasoning Paradigm: New Insights in Intellectually Disabled Patients. <b>2016</b> , 11, e0149717	6
112	Pharmacotherapy for mental health problems in people with intellectual disability. <b>2016</b> , 29, 103-25	50
111	Glutamate Delta-1 Receptor Regulates Metabotropic Glutamate Receptor 5 Signaling in the Hippocampus. <b>2016</b> , 90, 96-105	12
110	Advancing the understanding of autism disease mechanisms through genetics. <b>2016</b> , 22, 345-61	453

109	Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. <b>2016</b> , 8, 15	15
108	Fragile X Syndrome. <b>2016</b> , 751-764	1
107	Fragile X-associated tremor/ataxia syndrome: another phenotype of the fragile X gene. <b>2016</b> , 30, 810-4	4
106	Critical periods and neurodevelopmental brain disorders. <b>2016</b> , 73-98	
105	Brain in a Dish. <b>2016</b> , 117-132	1
104	The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions. <b>2016</b> , 8, 35	60
103	Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. <b>2016</b> , 60, 844-55	5
102	Fragile X syndrome: Current insight. <b>2016</b> , 17, 303-309	5
101	Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. <b>2016</b> , 8, 1	43
100	Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 321ra5	17.5 173
99	Clinical trials for neurodevelopmental disorders: At a therapeutic frontier. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 321fs1	17.5 36
98	Molecular medicine of fragile X syndrome: based on known molecular mechanisms. <b>2016</b> , 12, 19-27	5
97	Pharmacotherapy for Fragile X Syndrome: Progress to Date. <b>2016</b> , 76, 431-45	29
96	Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. <b>2016</b> , 73, 104-15	39
95	Finding FMR1 mosaicism in Fragile X syndrome. <b>2016</b> , 16, 501-7	14
94	Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome. <b>2016</b> , 80, 100-111	11
93	Partial mGluR Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. <b>2016</b> , 41, 1166-78	30
92	Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. <b>2016</b> , 17, 174-86	90

91	mGlu negative allosteric modulators: a patent review (2013 - 2016). <b>2017</b> , 27, 691-706	23
90	Enhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model. <b>2017</b> , 8, 14359	27
89	Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials. <b>2017</b> , 8, 7-8	19
88	Genetic Approaches to Understanding Psychiatric Disease. <b>2017</b> , 14, 564-581	3
87	Fragile X syndrome. <b>2017</b> , 3, 17065	257
86	Structure, Dynamics, and Modulation of Metabotropic Glutamate Receptors. <b>2017</b> , 129-147	1
85	Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways. <b>2017</b> , 18, 115-142	75
84	Drugs for rare disorders. <b>2017</b> , 83, 1607-1613	10
83	Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned. <b>2017</b> , 31, 235-244	1
82	Intellectual Disabilities and Global Developmental Delay. <b>2017</b> , 19-55	1
81	Fragile X targeted pharmacotherapy: lessons learned and future directions. <b>2017</b> , 9, 7	69
80	Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. <b>2017</b> , 9, 14	81
79	Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome. <b>2017</b> , 363-399	1
78	Fragile X Syndrome: Prevalence, Treatment, and Prevention in China. <b>2017</b> , 8, 254	8
77	Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously. <b>2017</b> , 10, 368	10
76	A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. <b>2017</b> , 9, 26	44
75	Human iPSC Models in Drug Discovery: Opportunities and Challenges. <b>2017</b> , 48-73	4
74	A systematic review of the methodological and practical challenges of undertaking randomised-controlled trials with cognitive disability populations. <b>2018</b> , 200, 114-128	19

73	Examining the influence of social-environmental variables on self-injurious behaviour in adolescent boys with fragile X syndrome. <b>2018</b> , 62, 1072-1085	8
72	Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. <b>2018</b> , 27, 2039-2051	31
71	Pharmacoeugenetics and Toxicoeugenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <b>2018</b> , 58, 161-185	36
70	Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. <b>2018</b> , 43, 503-512	74
69	A Summary of the Biological Processes, Disease-Associated Changes, and Clinical Applications of DNA Methylation. <b>2018</b> , 1708, 3-30	24
68	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. <b>2018</b> , 32, 3-29	116
67	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. <b>2018</b> , 17, 280-299	160
66	Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. <b>2018</b> , 8, 16970	24
65	Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective. <b>2018</b> , 8,	22
64	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. <b>2018</b> , 61, 8670-8692	18
63	Targeted Reactivation of Transcription in Fragile X Syndrome Embryonic Stem Cells. <b>2018</b> , 11, 282	28
62	Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. <b>2018</b> , 2, 497-507	180
61	Of Men and Mice: Modeling the Fragile X Syndrome. <b>2018</b> , 11, 41	64
60	Rescue of Fmr1 phenotypes with mGluR inhibitors: MRZ-8456 versus AFQ-056. <b>2018</b> , 119, 190-198	15
59	Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders. <b>2019</b> , 309-331	1
58	Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome. <b>2019</b> , 33, 975-985	3
57	Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome. <b>2019</b> , 14, e0209984	16
56	Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features. <b>2019</b> , 10, 21	15

55	Molecular Biomarkers in Fragile X Syndrome. <b>2019</b> , 9,	11
54	New Therapeutic Options for Fragile X Syndrome. <b>2019</b> , 21, 12	4
53	Larval zebrafish model for studying the effects of valproic acid on neurodevelopment: An approach towards modeling autism. <b>2019</b> , 95, 56-65	18
52	Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. <b>2020</b> , 1471, 18-56	31
51	The Role of Glutamate in Language and Language Disorders - Evidence from ERP and Pharmacologic Studies. <b>2020</b> , 119, 217-241	5
50	FMR1 mRNA from full mutation alleles is associated with ABC-C scores in males with fragile X syndrome. <b>2020</b> , 10, 11701	5
49	Association between human gray matter metabotropic glutamate receptor-5 availability in vivo and white matter properties: a [C]ABP688 PET and diffusion tensor imaging study. <b>2020</b> , 225, 1805-1816	
48	Adaptive Skills in FXS: A Review of the Literature and Evaluation of the PEDI-Computer Adaptive Test (PEDI-CAT) to Measure Adaptive Skills. <b>2020</b> , 10,	3
47	Fragile X clinical features and neurobiology. <b>2020</b> , 351-375	
46	Molecular analysis of alleles for fragile X syndrome diagnosis and patient stratification. <b>2020</b> , 20, 363-365	2
45	Evaluating Social Interactions Using the Autism Screening Instrument for Education Planning-3rd Edition (ASIEP-3): Interaction Assessment in Children and Adults with Fragile X Syndrome. <b>2020</b> , 10,	1
44	The multifaceted functional role of DNA methylation in immune-mediated rheumatic diseases. <b>2021</b> , 40, 459-476	9
43	Novel Therapeutic Approach for Excitatory/Inhibitory Imbalance in Neurodevelopmental and Neurodegenerative Diseases. <b>2021</b> , 61, 701-721	7
42	Adenosine A receptor inhibition reduces synaptic and cognitive hippocampal alterations in Fmr1 KO mice. <b>2021</b> , 11, 112	4
41	DNA Methylation, Mechanisms of Inactivation and Therapeutic Perspectives for Fragile X Syndrome. <b>2021</b> , 11,	5
40	An "Omic" Overview of Fragile X Syndrome. <b>2021</b> , 10,	3
39	Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments. <b>2021</b> , 12, 722378	1
38	Behavior in a Drosophila model of fragile X. <b>2012</b> , 54, 83-117	16



37	Intracellular Signaling Networks in Fragile X Syndrome: Approaches to Drug Discovery and Therapeutics. <b>2017</b> , 217-239	1
36	Overview of Targeted Double-Blind, Placebo-Controlled Clinical Trials in Fragile X Syndrome. <b>2017</b> , 401-418	3
35	Reflections on Clinical Trials in Fragile X Syndrome. <b>2017</b> , 419-441	1
34	Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators. <b>2020</b> , 88, 35-58	1
33	Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome. <b>2017</b> , 27, 850-863	2
32	International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors. <b>2021</b> , 73, 521-569	9
31	Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. <b>2011</b> , 6, e26203	238
30	Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients. <b>2015</b> , 10, e0131486	35
29	The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. <b>2014</b> , 12, 71-98	50
28	Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. <b>2013</b> , 8, 358-69	19
27	Receptor mapping using methoxy phenyl piperazine derivative: Preclinical PET imaging. <b>2021</b> , 117, 105429	0
26	Cytogenetics. <b>2011</b> , 394-414	
25	Inhibitory and Excitatory Systems in Autism Spectrum Disorders. <b>2013</b> , 335-346	0
24	Epigenomic and Noncoding RNA Regulation in Addictive Processes. <b>2013</b> , 115-165	
23	Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans. <b>2013</b> , 3, 637-650	
22	Medication Management of Fragile X Syndrome. <b>2014</b> , 2773-2783	1
21	Prenatal Diagnosis and the Spectrum of Involvement from Fragile X Mutations. 350-365	
20	What Mechanisms Induce Methylation of FMR1 Gene Full Mutation? A Still Unanswered Question. <b>2016</b> , 145-173	

19	Targeting the GABAB Receptor in Fragile X Syndrome and Autism Spectrum Disorders. <b>2016</b> , 251-261	
18	Epigenetic causes of intellectual disability in the fragile X syndrome paradigm. <b>2017</b> , 107-127	
17	Outcome Measures in Clinical Trials for Fragile X Syndrome: The Search for Sensitive Neurocognitive Assays. <b>2017</b> , 443-455	
16	Considering Medications for Behavior and Mental Health Problems. 245-270	
15	Fragile X clinical features and neurobiology. <b>2020</b> , 311-332	
14	Phase II and III drugs for the treatment of fragile X syndrome. <b>2013</b> , 1, 47-65	
13	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. <b>2014</b> , 23, 20-30	10
12	EEG as a translational biomarker and outcome measure in fragile X syndrome.. <b>2022</b> , 12, 34	1
11	Autism Drug Trial Tracker.	
10	Image_1.JPEG. <b>2018</b> ,	
9	Table_1.XLSX. <b>2018</b> ,	
8	Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?. <b>2022</b> , 13,	1
7	Maternal FMR1 alleles expansion in newborns during transmission: a prospective cohort study. <i>Pediatric Research</i> ,	3,2
6	From Genes to Therapy in Autism Spectrum Disorder. <b>2022</b> , 13, 1377	1
5	A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). <b>2022</b> , 14,	1
4	Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. <b>2023</b> , 15,	1
3	Epigenetic regulations in neurological disorders. <b>2023</b> , 269-310	0
2	Promises and challenges in pharmacoepigenetics. <b>2023</b> , 1,	0

- 1 Crosstalk between microRNAs and epigenetics during brain development and neurological diseases. **2023**, 173-207

o